Trial Profile

A Phase 1/2 Study of CBX-12 in Subjects with Advanced or Metastatic Refractory Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CBX 12 (Primary)
Indications Advanced breast cancer; Colorectal cancer; Gallbladder cancer; Malignant thymoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Cybrexa Therapeutics

Most Recent Events

23 Jan 2025 Planned End Date changed from 1 Mar 2025 to 1 Jun 2025.
23 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Mar 2025.
16 Sep 2024 According to a Cybrexa Therapeutics media release, data from the study were presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com